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Addenda I very much welcome the intention and the subject matter of the article by Velasco et al. However, several important issues were not mentioned. In uncomplicated urinary tract infections, resistance rates above 20% may be acceptable if other problems can be avoided.
Trimethoprim is as effective as co-trimoxazole but has far fewer side effects, especially allergy rates. Cotrimoxazole is therefore obsolete for this indication. The product information states that fosfomycin needs to be taken in a precise manner: no food intake two hours before ingestion and one hour afterwards, otherwise the effect may be lost even in susceptible pathogens. Most colleagues are not aware of this and stop using fosfomycin after disappointment with the treatment result.
Nitrofurantoin is licensed in Germany only in cases where alternatives cannot be used or are ineffective.
Most of these points are listed in the guideline published by the German College for General Practitioners and Family Physicians (Deutsche Gesellschaft für Allgemein-und Familienmedizin, DEGAM), "Burning Sensation When Passing Water". The authors of the article have obviously completely ignored this guideline. It is a shame that in conducting the study and preparing the publication, primary care physicians were not included.
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Methodological Flaws
The validity of the study reported by Velasco et al (1) is gravely hampered by methodological shortcomings.
The representativeness of the sample ("physicians providing outpatient care who gave uncomplicated UTI/cystitis as their most common diagnosis") seems to be questionable, since prescribing statistics show that respiratory tract infections are by far the most common cause for antibiotic prescriptions.
Jointly evaluating the responses from general practitioners and specialists does not make sense since the healthcare setting has a crucial influence on illness severity and treatment. Urologists care for patients with complicated urinary tract infections or infactions caused by problematic pathogens. Therefore urologists require a treatment that differs from the uncomplicated urinary tract infections that are typically dealt with in general practice.
The mono-substance trimethoprim (recommended in the evidence based guideline "Burning Sensation When Passing Water", by the German College for General Practitioners and Family Physicians [DEGAM]) does not seem to have been mentioned (in response to an open question) by any of the participants. Were the results (2) for trimethoprim (TMP) and trimethoprimsulfamethoxazole (TMP-SMX) combined? On the basis of recent study results (3) we think that TMP is still the antibiotic of choice. In any case, cotrimoxazole should not be suggested as a suitable alternative.
Current guidelines (DEGAM, AWMF [Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, Association of Scientific Medical Societies in Germany]) advise against identifying the pathogen in uncomplicated urinary tract infections. Resistance data, such as the cited German Antibiotic Resistance Surveillance System (ARS) can therefore not offer any insights into the resistance spectrum of uncomplicated infections.
A current comparison with unselected data from primary care (4) shows clear differences to the results from the ARS.
In conclusion, we recommend an analysis of the results presented in the current study for each healthcare setting, respectively. 
In Reply:
Schmiemann and colleagues see important methodological flaws in some aspects of our article (1) . We can dispel some of their fears on some points, but for others we could not proceed any differently because of the study design. Baum mentions similar issues. We still think our study is valid.
The representativeness of the sample has been extensively proven (2) . We provided a comparative overview of different guidelines. During the study period (2008), representatives from DEGAM were working on the completion of the newest S3 guideline; for this reason the guideline was not included in the overview. As the editorial introducing our article mentioned, our sampling period occurred about two years before the current publication of the S3 guideline on the treatment of uncomplicated urinary tract infections. In regions with resistance rates of below 20% for trimethoprim/ co-trimoxazole in E coli, trimethoprim/co-trimoxazole is still the antibiotic of choice (3). The selected antibiotic was entered as free text in our survey. Trimethoprim alone was mentioned only 39 times (0.01%), co-trimoxazole (combination of sulfonamides and trimethoprim) were mentioned 554 times (7%); we combined the results for this reason.
It is known that antibiotic resistance surveillance systems overestimate resistance rates in the outpatient setting. Studies such as the one by Schmiemann are therefore particularly important.
Lindner focuses on the possible influence of sample distribution to doctors by industry representatives. Possible factors of influence from the pharmaceutical industry, such as providing samples, are an important topic. This was discussed in depth during the focus groups preceding our survey (4). Possible influences from the pharmaceutical industry were discussed in our study. These factors did not, however, affect the prescribing of antibiotics in urinary tract infections.
